



### **Outstanding success for CytoTools AG: Clinical phase IIb study completed at subsidiary DermaTools Biotech GmbH with excellent cure rate of 92%**

- These results represent a breakthrough in treating diabetic foot, the most serious of chronic wounds caused by diabetes
- No side-effects were recorded in the 82 patients treated, underlining the outstanding safety of DermaPro®
- Completely new method of treatment for this chronic illness which was until today thought to be incurable, treated with a success rate of 92.3% after 12 weeks

Darmstadt, 22 August 2012 – CytoTools AG, a technology holding company with investments in the fields of pharmaceuticals and medical products, can report an incredible success at its subsidiary DermaTools Biotech GmbH. The results of the clinical European double-blind phase IIb study on the effectiveness of DermaPro® in the treatment of diabetic foot are now available. They show an outstanding effectiveness of 92.3% compared to 59.8% after a treatment period of 12 weeks. After eight weeks, the results were 90% compared to 41.3%. These wounds, which occur in up to one fifth of patients as a result of diabetes, are currently seen as being not effectively treatable from a medical point of view. The best medicines up to now achieved healing rates in the lower double-digit percentage range. DermaPro® is the world's first medicine to show clear effectiveness in clinical studies while at the same time recording excellent tolerance among patients as well as additional antiseptic effects. Following the outstanding effectiveness in phase IIb, the European phase III study can now be prepared with a lower number of patients than originally planned. After completely concluding the evaluations, the required documentation will be put together and submitted to the responsible authorities shortly so that phase III can be launched in the fourth quarter of this year if possible.

The management of DermaTools is delighted with the results of clinical phase IIb, as it means that a further important step towards the market launch of DermaPro® has now been completed. "In European phase IIb, 82 patients at centres in Germany, Latvia and Lithuania were treated. In the control group, one of the best standard therapies, moist wound dressings, were used. The evaluation recorded very clear results, meaning that the primary endpoint of the study has been reached," explains Dr. Dirk Kaiser, Managing Director of DermaTools Biotech GmbH. The market launch of DermaPro® in India, which is planned for the next year, will underline the great commercial potential of this patented new substance for the first time. Moreover, in a further step,

## **PRESS INFORMATION**



additional indications of chronic wounds and wounds susceptible to infection are to be treated in clinical phases in order to document the wide-ranging uses of DermaPro® and to substantially expand its possible range of applications.

*This release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.*

**CytoTools AG**, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: approx. 60% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of exclusive licenses.

### **Contact:**

CytoTools AG  
Dr. Mark Andre Freyberg  
Klappacher Str. 126  
64285 Darmstadt, Germany  
Tel.: +49-6151-95158-12  
Fax: +49-6151-95158-13  
E-Mail: [freyberg@cytotools.de](mailto:freyberg@cytotools.de)

### **Press contact:**

cometis AG  
Ulrich Wiehle  
Unter den Eichen 7  
65195 Wiesbaden, Germany  
Tel.: +49-611-205855-11  
Fax: +49-611-205855-66  
E-Mail: [wiehle@cometis.de](mailto:wiehle@cometis.de)